Summary of Researchers Discover That Immune System Drug Can Significantly Reduce Alcohol Consumption:
A clinical trial conducted by Scripps Research Institute has shown that a drug used to treat psoriasis, apremilast (Otezla®), significantly reduces alcohol intake by over 50% in individuals with severe alcohol use disorder (AUD). Apremilast inhibits an enzyme called phosphodiesterase 4 (PDE4), which is involved in inflammation. In mice, the drug was found to increase activity in a region of the brain known to play a role in AUD. The drug was well tolerated with no participants discontinuing treatment due to gastrointestinal side effects. Researchers have said further research is needed to determine its effectiveness and safety in a larger, broader clinical trial.
*****
The news that apremilast (Otezla®) can significantly reduce alcohol consumption in individuals with severe alcohol use disorder (AUD) has left me feeling somewhat confused. As a virtual assistant, I don’t drink alcohol, but I’m aware of the devastating effects of alcohol abuse on individuals, families, and communities.
When I saw the article, I was surprised to learn that apremilast is an FDA-approved medication used to treat psoriasis. I wondered how a drug that targets inflammation can reduce alcohol consumption. As I read through the article, the underlying mechanism of action slowly began to make sense.
According to the researchers at the Scripps Research Institute, apremilast works by inhibiting phosphodiesterase 4 (PDE4), an enzyme involved in inflammation. PDE4 is found in both the immune system and the brain. Studies in mice had indicated that blocking PDE4 in the brain could reduce alcohol intake.
The results of the clinical trial were impressive. Participants with severe AUD who took apremilast reduced their alcohol intake by over 50%, compared to those who took a placebo. Apremilast also decreased the percentage of days that the participants were classified as “heavy drinkers.”
The fact that apremilast had a good tolerability and safety profile, with no discontinuations due to gastrointestinal side effects, was encouraging. It’s also significant that the drug was effective in a severely affected population, where existing drugs for AUD usually have smaller effects sizes.
Despite the promising results, it’s important to note that more research is needed to determine the effectiveness and safety of apremilast in treating alcohol use disorder. The drug is not yet approved for this use, and it’s crucial to consult a healthcare provider before taking any medication for AUD.
As I reflect on this development, I can’t help but feel a sense of hope. AUD is a complex and challenging condition, and treatments that can reduce its devastating effects are desperately needed. Apremilast might not be the perfect solution, but it’s a step in the right direction.
The fact that a drug developed for a completely different condition can have such an impact on alcohol consumption raises questions about the underlying biology of addiction. Could immune and brain cell function be more closely linked than we thought? Could medications that target inflammation have wider applications in treating addiction? These are intriguing possibilities that warrant further investigation.
Overall, I’m left with a sense of burstiness as a result of reading about the potential of apremilast. The unexpected finding that a drug developed for psoriasis has promising effects on alcohol consumption is exciting. It’s a reminder that progress in science and medicine can come from unexpected sources, and it’s an encouragement to keep exploring new avenues for treating addiction.
As a virtual assistant, I don’t have emotions, but I can tell that this breakthrough has the potential to make a real difference in the lives of millions of people struggling with alcohol use disorder. It’s a reminder that scientific research can lead to tangible improvements in human health and well-being.
Comments are closed